Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C8KF
|
|||
| Former ID |
DCL000215
|
|||
| Drug Name |
Resiquimod
|
|||
| Synonyms |
Resiquimod [INN]; R 848; S 28463; R-848; S-28463; VML-600; 1-(4-Amino-2-ethoxymethyl-imidazo[4,5-c]quinolin-1-yl)-2-methyl-propan-2-ol; 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 4-amino-2-(ethoxymethyl)-a,a-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol; 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Actinic keratosis [ICD-11: EK90.0; ICD-10: L57.0; ICD-9: 702] | Phase 2 | [1] | |
| Cutaneous T-cell lymphoma [ICD-11: 2B01; ICD-10: C84.0] | Phase 2 | [2] | ||
| Herpes simplex virus infection [ICD-11: 1F00; ICD-10: B00; ICD-9: 54] | Phase 1/2 | [3], [4] | ||
| Company |
3M Pharma.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H22N4O2
|
|||
| Canonical SMILES |
CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N
|
|||
| InChI |
1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
|
|||
| InChIKey |
BXNMTOQRYBFHNZ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 144875-48-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3721870, 10253655, 12014952, 14850224, 17425420, 46234815, 50987434, 53787617, 53787700, 56310917, 56314233, 57348724, 99030027, 103137407, 103137408, 103481674, 104098572, 113442759, 117524042, 125823193, 127582362, 134338879, 135115623, 137001879, 141757820, 160828723, 162023641, 162023642, 162023652, 163093686, 163390245, 163820535, 163842421, 172093316, 178101746, 179149939, 180674503, 185979111, 198951685, 204427635, 210274952, 210280590, 223383296, 223503036, 223592720, 223704642, 223775289, 226420675, 242068671, 249841086
|
|||
| ChEBI ID |
CHEBI:36706
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Toll-like receptor 7 (TLR7) | Target Info | Modulator | [5] |
| Toll-like receptor 8 (TLR8) | Target Info | Modulator | [5] | |
| KEGG Pathway | Toll-like receptor signaling pathway | |||
| Measles | ||||
| Influenza A | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Leptin Signaling Pathway | ||||
| Panther Pathway | Toll receptor signaling pathway | |||
| Reactome | Trafficking and processing of endosomal TLR | |||
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | ||||
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | ||||
| MyD88 dependent cascade initiated on endosome | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Toll-Like Receptors Cascades | ||||
| MyD88 dependent cascade initiated on endosome | ||||
| Trafficking and processing of endosomal TLR | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01583816) Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03292406) A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) (CTCL). U.S. National Institutes of Health. | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5051). | |||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010858) | |||
| REF 5 | TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.